Your browser doesn't support javascript.
loading
Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls.
Bellenguez, Céline; Charbonnier, Camille; Grenier-Boley, Benjamin; Quenez, Olivier; Le Guennec, Kilan; Nicolas, Gaël; Chauhan, Ganesh; Wallon, David; Rousseau, Stéphane; Richard, Anne Claire; Boland, Anne; Bourque, Guillaume; Munter, Hans Markus; Olaso, Robert; Meyer, Vincent; Rollin-Sillaire, Adeline; Pasquier, Florence; Letenneur, Luc; Redon, Richard; Dartigues, Jean-François; Tzourio, Christophe; Frebourg, Thierry; Lathrop, Mark; Deleuze, Jean-François; Hannequin, Didier; Genin, Emmanuelle; Amouyel, Philippe; Debette, Stéphanie; Lambert, Jean-Charles; Campion, Dominique.
Affiliation
  • Bellenguez C; Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France; Institut Pasteur de Lille, Lille, France; University Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France.
  • Charbonnier C; Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
  • Grenier-Boley B; Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France; Institut Pasteur de Lille, Lille, France; University Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France.
  • Quenez O; Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
  • Le Guennec K; Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
  • Nicolas G; Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
  • Chauhan G; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France.
  • Wallon D; Department of Neurology and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
  • Rousseau S; Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
  • Richard AC; Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
  • Boland A; Centre National de Génotypage, Institut de Génomique, CEA, Evry, France.
  • Bourque G; McGill University and Génome Québec Innovation Centre, Montréal, Canada.
  • Munter HM; McGill University and Génome Québec Innovation Centre, Montréal, Canada.
  • Olaso R; Centre National de Génotypage, Institut de Génomique, CEA, Evry, France.
  • Meyer V; Centre National de Génotypage, Institut de Génomique, CEA, Evry, France.
  • Rollin-Sillaire A; CNR-MAJ, and Department of Neurology, Université de Lille, CHU, Inserm UMR-S 1171, Lille, France.
  • Pasquier F; CNR-MAJ, and Department of Neurology, Université de Lille, CHU, Inserm UMR-S 1171, Lille, France.
  • Letenneur L; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France.
  • Redon R; Inserm UMR-1087/CNRS UMR 6291, l'institut du thorax, Univ. Nantes, Nantes, France.
  • Dartigues JF; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France.
  • Tzourio C; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France.
  • Frebourg T; Department of Genetics, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
  • Lathrop M; McGill University and Génome Québec Innovation Centre, Montréal, Canada.
  • Deleuze JF; Centre National de Génotypage, Institut de Génomique, CEA, Evry, France.
  • Hannequin D; Department of Neurology and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France; Department of Genetics, Neurology and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Norman
  • Genin E; Inserm UMR-1078, CHRU Brest, Univ. Brest, Brest, France.
  • Amouyel P; Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France; Institut Pasteur de Lille, Lille, France; University Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France; Centre Hospitalier Universitaire de Lille, Epidemiology and Public Health Dep
  • Debette S; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France.
  • Lambert JC; Inserm, U1167, RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille, France; Institut Pasteur de Lille, Lille, France; University Lille, U1167-Excellence Laboratory LabEx DISTALZ, Lille, France. Electronic address: jean-charles.lambert@pasteur-lille.fr.
  • Campion D; Department of Genetics and CNR-MAJ, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen, France; Department of Research, Centre hospitalier du Rouvray, Sotteville-lès-Rouen, France. Electronic address: dominique.campion@u
Neurobiol Aging ; 59: 220.e1-220.e9, 2017 11.
Article in En | MEDLINE | ID: mdl-28789839
We performed whole-exome and whole-genome sequencing in 927 late-onset Alzheimer disease (LOAD) cases, 852 early-onset AD (EOAD) cases, and 1273 controls from France. We assessed the evidence for gene-based association of rare variants with AD in 6 genes for which an association with such variants was previously claimed. When aggregating protein-truncating and missense-predicted damaging variants, we found exome-wide significant association between EOAD risk and rare variants in SORL1, TREM2, and ABCA7. No exome-wide significant signal was obtained in the LOAD sample, and significance of the order of 10-6 was observed in the whole AD group for TREM2. Our study confirms previous gene-level results for TREM2, SORL1, and ABCA7 and provides a clearer insight into the classes of rare variants involved. Despite different effect sizes and varying cumulative minor allele frequencies, the rare protein-truncating and missense-predicted damaging variants in TREM2, SORL1, and ABCA7 contribute similarly to the heritability of EOAD and explain between 1.1% and 1.5% of EOAD heritability each, compared with 9.12% for APOE ε4.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Membrane Transport Proteins / Genetic Variation / Membrane Glycoproteins / Receptors, Immunologic / ATP-Binding Cassette Transporters / Genetic Predisposition to Disease / LDL-Receptor Related Proteins / Genome-Wide Association Study / Genetic Association Studies / Alzheimer Disease Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Neurobiol Aging Year: 2017 Type: Article Affiliation country: France

Full text: 1 Database: MEDLINE Main subject: Membrane Transport Proteins / Genetic Variation / Membrane Glycoproteins / Receptors, Immunologic / ATP-Binding Cassette Transporters / Genetic Predisposition to Disease / LDL-Receptor Related Proteins / Genome-Wide Association Study / Genetic Association Studies / Alzheimer Disease Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Neurobiol Aging Year: 2017 Type: Article Affiliation country: France